stockrow
Friday 6 November 2026
Export INDP’s income statement to Excel — free account
Indaptus Therapeutics, Inc.
INDP Healthcare Biotechnology
- EPS
- +99.8%
- Free cash flow
- +52.0%
Quarter to June 2026, against a year earlier
3.34
0.18
+5.70%
Follow INDP
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | 42 | 42 | 42 | 0.0% | |
| Gross margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 | 0.0 pt | ||||||
| EBT | (13) | (29) | (43) | (47) | (4) | (8) | (14) | (15) | (15) | (21) | (15) | +5.1% | ||||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | (13) | (29) | (44) | (48) | (4) | (8) | (14) | (15) | (15) | (21) | (15) | +5.1% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | (2,621.85) | (3,697.48) | (3,137.25) | (3,159.66) | (51.63) | (52.94) | (48.46) | (51.26) | (45.10) | (21.58) | (7.75) | (41.3%) | ||||||
| Cash flow | (2,353.92) | (2,801.52) | (2,811.22) | (1,923.51) | (47.90) | (77.33) | (44.33) | (44.70) | (36.88) | (15.34) | (0.13) | (42.8%) | ||||||
| Capex | (94.51) | (632.15) | (335.76) | (60.99) | (0.32) | (0.03) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | (2,448.43) | (3,433.67) | (3,146.98) | (1,984.50) | (48.22) | (77.36) | (44.33) | (44.70) | (36.88) | (15.34) | (0.13) | (43.1%) | ||||||
| Book value | 4,451.76 | 7,443.29 | 3,852.16 | 763.91 | (3.43) | 245.89 | 83.49 | 40.27 | 11.81 | 3.26 | 0.10 | (55.2%) | ||||||
| Shares, m | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 32 | +79.1% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (12) | (22) | (39) | (29) | (3) | (11) | (13) | (13) | (12) | (15) | (15) | +2.4% | |||||
| Capex | 0 | (5) | (5) | (1) | 0 | 0 | — | — | — | — | 0 | (61.8%) | ||||||
| Free cash flow | (12) | (27) | (44) | (30) | (3) | (11) | (13) | (13) | (12) | (15) | (15) | +1.9% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 19 | 51 | 36 | 5 | 0 | 36 | 24 | 11 | 3 | 3 | 11 | (18.0%) | |||||
| Net debt | (18) | (55) | (41) | (10) | (2) | (39) | (26) | (13) | (6) | (9) | (12) | (8.1%) | ||||||
| Shareholders’ equity | 23 | 59 | 54 | 12 | 0 | 36 | 25 | 12 | 4 | 3 | 11 | (19.7%) | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (43.18) | (64.77) | (69.08) | (114.99) | (31.09) | (36.41) | (41.73) | (71.76) | (134.95) | (250.45) | (163.84) | (207.3) pt | |||||
| ROIC | (192.86) | (513.38) | (208.85) | (1,998.85) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | +192.9 pt | ||||||
| ROE | (45.89) | (70.94) | (77.52) | (146.28) | (63.50) | (43.26) | (47.32) | (84.04) | (187.52) | (588.41) | (318.04) | (542.5) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 56 | 70 | 83 | 49 | 45 | 5 | 6 | 7 | 7 | 5 | — | (23.5%) | |||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fundamentals updated 26 Oct 2026
Indaptus Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| SLBT SL SCIENCE HLDG | $504.7M | — | — | — | — | — | — | — | Compare |
| PBYI Puma Biotechnology, Inc. | $504.3M | 15.3× | 24.2× | +7.75% (above 0%: growing) | +33.33% (above 0%: growing) | −88.45% (below 0%: shrinking) | 77.92% | 13.42% | Compare |
| OVID Ovid Therapeutics | $503.9M | — (loss-making) | — (loss-making) | +463.85% (above 0%: growing) | n/m | −268.54% (below 0%: shrinking) | 100.00% | (2,141.61%) | Compare |
| CAPR Capricor Therapeutics, Inc. | $500.0M | — (loss-making) | — (loss-making) | −7.92% (below 0%: shrinking) | n/m | −72.88% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| DMAC DiaMedica Therapeutics, Inc. | $487.5M | — (loss-making) | — (loss-making) | — | n/m | −6.75% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| RGNX REGENXBIO Inc. | $487.2M | — (loss-making) | — (loss-making) | −69.19% (below 0%: shrinking) | n/m | +168.05% (above 0%: growing) | 87.55% | (387.84%) | Compare |
| INDP Indaptus Therapeutics, Inc. | $485.3M | — (loss-making) | — | — | n/m | +52.03% (above 0%: growing) | 0.00% | 0.00% | |
| CBIO Crescent Biopharma, Inc. | $480.6M | — (loss-making) | — (loss-making) | +1,038,900.00% (above 0%: growing) | n/m | −7.04% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| MDXG MiMedx Group, Inc | $478.6M | — (loss-making) | — (loss-making) | −45.23% (below 0%: shrinking) | n/m | −87.21% (below 0%: shrinking) | 79.80% | (18.79%) | Compare |
| Median of peers | $493.7M | — | — | −0.09% | — | −72.88% | 87.55% | 0.00% |